ID

29846

Descripción

https://www.gsk-clinicalstudyregister.com/study/104864/201?search=study&#rs Study ID: 104864-201 Clinical Study ID: 104864/A201 Study Title: A Phase III, Open-Label, Multicenter, Randomized, Comparative Study of Topotecan, Ara-C and G-CSF (TAG) versus Idarubicin, Ara-C and G-CSF (IDAG) in MDS Patients with RAEB (High-Risk), RAEB-t or in Patients with AML from a Preceding Phase of MDS Patient Level Data: Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: topotecan Trade Name: hycamtin Study Indication: Myelodysplastic Syndrome

Link

https://www.gsk-clinicalstudyregister.com/study/104864/201?search=study&#rs

Palabras clave

Versiones (1)
  1. 24/4/18 24/4/18 - Halim Ugurlu
Titular de derechos de autor

GSK

Subido en

24 de abril de 2018

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY-NC 3.0
Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Volver a los comentarios del modelo
Comentarios de grupo de elementos para :

Comentarios del elemento para :

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

GSK Study ID 104864-201 Inclusion-Exclusion Criteria and Telephone Randomisation

Inglés

Inclusion-Exclusion Criteria and Telephone Randomisation

1 formularios  
Identification Numbers
Descripción

Identification Numbers

Alias
UMLS CUI-1
C1300638
Patient Number
Descripción

Patient Number

Tipo de datos

text

Alias
UMLS CUI [1]
C1830427
Patient Initials
Descripción

Patient Initials

Tipo de datos

text

Alias
UMLS CUI [1]
C2986440
Inclusion Criteria-Do not admit the patient to this study if any "No" box has been marked
Descripción

Inclusion Criteria-Do not admit the patient to this study if any "No" box has been marked

Alias
UMLS CUI-1
C1512693
Written informed consent (see Sample Informed Consent Form protocol Appendix E)
Descripción

Written informed consent

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0021430
At least 18 years of age
Descripción

Age

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0001779
Diagnosis
Descripción

a)Diagnosis of myelodysplastic syndrome, subcategories of refractory anemia with excess of blasts, INT 2 or high risk (RAEB) as defined by Greenberg, et al, [4] (see protocol Appendix L), or refractory anemia with excess of blasts in transformation (RAEB-t) OR b)Diagnosis of AML which has evolved from a preceding phase of MDS defined as the presence of antecedent hematologic disorder existing for at least the past three months, AML and/or poor prognosis cytogenetics.

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0011900
UMLS CUI [1,2]
C0023467
UMLS CUI [2,1]
C0011900
UMLS CUI [2,2]
C3463824
Performance Status and life expectancy
Descripción

Performance status <= 2 (Zubrod-ECOG-WHO cale, protocol Appendix C) and life expectancy =>6 weeks.

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C1520224
UMLS CUI [1,2]
C0023671
Prior Chemotherapy
Descripción

Patients must not have received prior chemotherapy except low-dose ara-C, hydroxyurea, or intrathecal methotrexate for MDS or AML.

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C1514457
UMLS CUI [1,2]
C0332300
UMLS CUI [1,3]
C0010711
UMLS CUI [1,4]
C1707814
UMLS CUI [1,5]
C0025677
UMLS CUI [1,6]
C0677897
Recovery from all toxicities
Descripción

Recovery from all toxicities since last chemotherapy and/or biologic therapy, unless specific conditions discussed with medical monitor.

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0013221
UMLS CUI [1,2]
C2004454
Previous malignancies
Descripción

Patients with previous malignancies in CR for one year or greater.

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C2735088
UMLS CUI [1,2]
C0006826
Not being candidate for curative allogenic bone marrow transplant
Descripción

Patients must not be candidates for curative allogenic bone marrow transplant at the time of treatment, although it is recognized they may become candidates at a future time (i.e., a matched donor is found).

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0030705
UMLS CUI [1,2]
C1548788
UMLS CUI [1,3]
C0149615
Limited Laboratory Values
Descripción

Current laboratory values within the limits listed below unless agreed upon by the principal investigator and the medical monitor: - creatinine <= 1.5 mg/dL (133 micromol/l) - serum bilirubin <= 2.0 mg/dL (34 micromol/l) SGOT/SGPT <= 2 times the upper limit of normal

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0022877
UMLS CUI [1,2]
C0042295
Left ventricular ejection fraction
Descripción

Patients must have a left ventricular ejection fraction (LVEF) of at least 50%

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0428772
Exclusion Criteria-Do not admit the patient to this study if any "Yes" box has been marked
Descripción

Exclusion Criteria-Do not admit the patient to this study if any "Yes" box has been marked

Alias
UMLS CUI-1
C0680251
Eligibilty for curative allogenic bone marrow transplant
Descripción

Patients who are eligible for curative allogenic bone marrow transplant without additional treatment.

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0149615
UMLS CUI [1,2]
C0013893
Patients with chromosomal abnormalities
Descripción

Patients with chromosomal abnormalities of t(15;17), t(8;21), or inv(16)

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0008625
UMLS CUI [1,2]
C2348235
Patients with CMML
Descripción

Patients with CMML.

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0023480
Less than 3 weeks since major surgery
Descripción

Less than 3 weeks since major surgery, except for placement of central line.

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0679637
UMLS CUI [1,2]
C0087111
UMLS CUI [1,3]
C0040223
Concomitant malignancies
Descripción

Concomitant malignancies with the exception of curatively treated basal cell carcinoma of the skin, carcinoma in situ of the cervix and previous malignancies in CR for less than one year.

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0006826
UMLS CUI [1,2]
C0332196
UMLS CUI [1,3]
C0007114
UMLS CUI [1,4]
C2216722
UMLS CUI [1,5]
C0242793
Concurrent severe medical problems unrelated to the malignancy
Descripción

Concurrent severe medical problems unrelated to the malignancy which would significantly limit the full compliance with the study or expose the patient to extreme risk.

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0009488
UMLS CUI [1,2]
C0205082
Uncontrolled or severe cardiovascular disease
Descripción

Uncontrolled or severe cardiovascular disease including recent (< 3 months) myocardial infarction or congestive heart failure.

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0007222
UMLS CUI [1,2]
C0205318
UMLS CUI [1,3]
C0205082
Active infection
Descripción

Active infection

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C3714514
UMLS CUI [1,2]
C0205177
History of (+) HIV
Descripción

Patients who have a history of (+) HIV.

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0019693
UMLS CUI [1,2]
C0262926
Patients who have (+) PPD with abnormal CXR
Descripción

Patients who have (+) PPD with abnormal CXR

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0032739
UMLS CUI [1,2]
C2041426
UMLS CUI [1,3]
C0205161
Females of child-bearing potential, not practicing adequate contraception
Descripción

Females of child-bearing potential, not practicing adequate contraception. Females of child-bearing potential, premenopausal (less than 60 years of age), or not surgically sterilized must use effective contraception by barrier method contraception, an interuterine device (IUD) or use of birth control pill for 3 months prior to entry into the study and agree to continue to use it during the study and for at least 4 weeks after the end of study drug administration.

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C1960468
UMLS CUI [1,2]
C0700589
Pregnancy or lactation.
Descripción

Pregnancy or lactation.

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2]
C0006147
Use of an investigational drug
Descripción

Use of an investigational drug (including a cytotoxic drug) within 30 days or 5 half-lives (whichever is longer) preceding the first dose of study medication.

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0013230
UMLS CUI [1,2]
C0040223
Concurrent use of other chemotherapy
Descripción

Concurrent use of other chemotherapy

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0003392
UMLS CUI [1,2]
C4060806
Any chemotherapy with topotecan or idarubicin
Descripción

Any chemotherapy with topotecan or idarubicin

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C3665472
UMLS CUI [1,2]
C0146224
UMLS CUI [2]
C0020789
History of hypersensitivity to compounds chemically related to topotecan, ara-C, idarubicin or G-CSF.
Descripción

History of hypersensitivity to compounds chemically related to topotecan, ara-C, idarubicin or G-CSF.

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0020517
UMLS CUI [1,2]
C0146224
UMLS CUI [1,3]
C0733521
UMLS CUI [1,4]
C0020789
UMLS CUI [1,5]
C0079459
Patient known to be refractory to "platelet transfusions."
Descripción

Patient known to be refractory to "platelet transfusions."

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0086818
UMLS CUI [1,2]
C0205269
Telephone Randomisation
Descripción

Telephone Randomisation

Alias
UMLS CUI-1
C0039457
UMLS CUI-2
C0034656
Has a randomized number been obtained for the patient using the centralized telephone number?
Descripción

Telephone Randomisation

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0039457
UMLS CUI [1,2]
C0034656
If Yes to Telephone Randomisation
Descripción

If Yes to Telephone Randomisation

Alias
UMLS CUI-1
C0039457
UMLS CUI-2
C0034656
Randomization Number
Descripción

Please record the patient's randomization number

Tipo de datos

text

Alias
UMLS CUI [1,1]
C1300638
UMLS CUI [1,2]
C0034656
Regimen
Descripción

Please indicate which regimen the patient is scheduled to receive below

Tipo de datos

text

Alias
UMLS CUI [1]
C0392920
Volver a la parte superior de la página

Similar models

Inclusion-Exclusion Criteria and Telephone Randomisation

1 formularios
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Item Group
Identification Numbers
C1300638 (UMLS CUI-1)
Patient Number
Item
Patient Number
text
C1830427 (UMLS CUI [1])
Patient Initials
Item
Patient Initials
text
C2986440 (UMLS CUI [1])
Item Group
Inclusion Criteria-Do not admit the patient to this study if any "No" box has been marked
C1512693 (UMLS CUI-1)
Written informed consent
Item
Written informed consent (see Sample Informed Consent Form protocol Appendix E)
boolean
C0021430 (UMLS CUI [1])
Age
Item
At least 18 years of age
boolean
C0001779 (UMLS CUI [1])
Diagnosis
Item
Diagnosis
boolean
C0011900 (UMLS CUI [1,1])
C0023467 (UMLS CUI [1,2])
C0011900 (UMLS CUI [2,1])
C3463824 (UMLS CUI [2,2])
Performance Status and life expectancy
Item
Performance Status and life expectancy
boolean
C1520224 (UMLS CUI [1,1])
C0023671 (UMLS CUI [1,2])
Prior Chemotherapy
Item
Prior Chemotherapy
boolean
C1514457 (UMLS CUI [1,1])
C0332300 (UMLS CUI [1,2])
C0010711 (UMLS CUI [1,3])
C1707814 (UMLS CUI [1,4])
C0025677 (UMLS CUI [1,5])
C0677897 (UMLS CUI [1,6])
Recovery from all toxicities
Item
Recovery from all toxicities
boolean
C0013221 (UMLS CUI [1,1])
C2004454 (UMLS CUI [1,2])
Previous malignancies
Item
Previous malignancies
boolean
C2735088 (UMLS CUI [1,1])
C0006826 (UMLS CUI [1,2])
Not being candidate for curative allogenic bone marrow transplant
Item
Not being candidate for curative allogenic bone marrow transplant
boolean
C0030705 (UMLS CUI [1,1])
C1548788 (UMLS CUI [1,2])
C0149615 (UMLS CUI [1,3])
Limited Laboratory Values
Item
Limited Laboratory Values
boolean
C0022877 (UMLS CUI [1,1])
C0042295 (UMLS CUI [1,2])
Left ventricular ejection fraction
Item
Left ventricular ejection fraction
boolean
C0428772 (UMLS CUI [1])
Item Group
Exclusion Criteria-Do not admit the patient to this study if any "Yes" box has been marked
C0680251 (UMLS CUI-1)
Eligibilty for curative allogenic bone marrow transplant
Item
Eligibilty for curative allogenic bone marrow transplant
boolean
C0149615 (UMLS CUI [1,1])
C0013893 (UMLS CUI [1,2])
Patients with chromosomal abnormalities
Item
Patients with chromosomal abnormalities
boolean
C0008625 (UMLS CUI [1,1])
C2348235 (UMLS CUI [1,2])
Patients with CMML
Item
Patients with CMML
boolean
C0023480 (UMLS CUI [1])
Major surgery
Item
Less than 3 weeks since major surgery
boolean
C0679637 (UMLS CUI [1,1])
C0087111 (UMLS CUI [1,2])
C0040223 (UMLS CUI [1,3])
Concomitant malignancies
Item
Concomitant malignancies
boolean
C0006826 (UMLS CUI [1,1])
C0332196 (UMLS CUI [1,2])
C0007114 (UMLS CUI [1,3])
C2216722 (UMLS CUI [1,4])
C0242793 (UMLS CUI [1,5])
Concurrent severe medical problems unrelated to the malignancy
Item
Concurrent severe medical problems unrelated to the malignancy
boolean
C0009488 (UMLS CUI [1,1])
C0205082 (UMLS CUI [1,2])
Uncontrolled or severe cardiovascular disease
Item
Uncontrolled or severe cardiovascular disease
boolean
C0007222 (UMLS CUI [1,1])
C0205318 (UMLS CUI [1,2])
C0205082 (UMLS CUI [1,3])
Active infection
Item
Active infection
boolean
C3714514 (UMLS CUI [1,1])
C0205177 (UMLS CUI [1,2])
History of (+) HIV
Item
History of (+) HIV
boolean
C0019693 (UMLS CUI [1,1])
C0262926 (UMLS CUI [1,2])
Patients who have (+) PPD with abnormal CXR
Item
Patients who have (+) PPD with abnormal CXR
boolean
C0032739 (UMLS CUI [1,1])
C2041426 (UMLS CUI [1,2])
C0205161 (UMLS CUI [1,3])
Females of child-bearing potential, not practicing adequate contraception
Item
Females of child-bearing potential, not practicing adequate contraception
boolean
C1960468 (UMLS CUI [1,1])
C0700589 (UMLS CUI [1,2])
Pregnancy or lactation.
Item
Pregnancy or lactation.
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
Use of an investigational drug
Item
Use of an investigational drug
boolean
C0013230 (UMLS CUI [1,1])
C0040223 (UMLS CUI [1,2])
Concurrent use of other chemotherapy
Item
Concurrent use of other chemotherapy
boolean
C0003392 (UMLS CUI [1,1])
C4060806 (UMLS CUI [1,2])
Any chemotherapy with topotecan or idarubicin
Item
Any chemotherapy with topotecan or idarubicin
boolean
C3665472 (UMLS CUI [1,1])
C0146224 (UMLS CUI [1,2])
C0020789 (UMLS CUI [2])
History of hypersensitivity
Item
History of hypersensitivity to compounds chemically related to topotecan, ara-C, idarubicin or G-CSF.
boolean
C0020517 (UMLS CUI [1,1])
C0146224 (UMLS CUI [1,2])
C0733521 (UMLS CUI [1,3])
C0020789 (UMLS CUI [1,4])
C0079459 (UMLS CUI [1,5])
Patient known to be refractory to "platelet transfusions."
Item
Patient known to be refractory to "platelet transfusions."
boolean
C0086818 (UMLS CUI [1,1])
C0205269 (UMLS CUI [1,2])
Item Group
Telephone Randomisation
C0039457 (UMLS CUI-1)
C0034656 (UMLS CUI-2)
Telephone Randomisation
Item
Has a randomized number been obtained for the patient using the centralized telephone number?
boolean
C0039457 (UMLS CUI [1,1])
C0034656 (UMLS CUI [1,2])
Item Group
If Yes to Telephone Randomisation
C0039457 (UMLS CUI-1)
C0034656 (UMLS CUI-2)
Randomization Number
Item
Randomization Number
text
C1300638 (UMLS CUI [1,1])
C0034656 (UMLS CUI [1,2])
Item
Regimen
text
C0392920 (UMLS CUI [1])
Regimen
Code List
Regimen
CL Item
Topotecan, ara-C G-CSF (TA)
CL Item
Idarubicin, ara-C G-CSF (AA)
Volver a la parte superior de la página 

Contacto

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Ayuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial